Organogenesis (ORGO) Projected to Post Quarterly Earnings on Thursday

Key Points

• Organogenesis is expected to report Q3 2026 results after market close on November 5. Analysts project a loss of $0.175 per share and revenue of $52.10 million.
• The company’s previous quarter significantly missed expectations, reporting a $0.71 per-share loss versus a projected $0.35 loss and revenue of $43.76 million versus estimates of $54.27 million.
• ORGO shares remain under pressure, trading near their 52-week low at $0.82. Analysts’ consensus rating is “Reduce,” with a $4.33 price target, while recent ratings include two Holds and one Sell.

Organogenesis (NASDAQ:ORGO - Get Free Report) is anticipated to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($0.1750) per share and revenue of $52.10 million for the quarter. Parties are encouraged to explore the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:00 PM ET.

Organogenesis (NASDAQ:ORGO - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.36). Organogenesis had a negative net margin of 19.94% and a negative return on equity of 23.89%. The business had revenue of $43.76 million during the quarter, compared to analyst estimates of $54.27 million.

Organogenesis Price Performance

Shares of NASDAQ:ORGO opened at $0.82 on Thursday. The company has a quick ratio of 3.00, a current ratio of 3.52 and a debt-to-equity ratio of 0.07. Organogenesis has a fifty-two week low of $0.81 and a fifty-two week high of $7.08. The firm has a 50-day simple moving average of $1.40 and a 200 day simple moving average of $2.42. The company has a market cap of $106.12 million, a PE ratio of -0.96 and a beta of 1.27.

Analyst Ratings Changes

A number of equities analysts have issued reports on ORGO shares. Wall Street Zen raised shares of Organogenesis from a "strong sell" rating to a "sell" rating in a report on Saturday, September 19th. Truist Financial lowered their target price on Organogenesis from $3.00 to $2.00 and set a "hold" rating for the company in a report on Friday, August 7th. Finally, Weiss Ratings lowered Organogenesis from a "sell (d-)" rating to a "sell (e+)" rating in a report on Monday, October 19th. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Reduce" and a consensus price target of $4.33.

Organogenesis Company Profile

Organogenesis Holdings Inc is a biotechnology company that develops, manufactures and commercializes products intended to support tissue regeneration and wound healing. The company serves the advanced wound care and surgical and sports medicine markets, with a focus on therapies that help manage complex wounds and support the repair of damaged tissue.

Its product portfolio includes bioengineered skin substitutes and other biologic products, such as Apligraf, Dermagraft, NuShield, Affinity and NuCel.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.